ArticlePloS one2013
Next generation inactivated polio vaccine manufacturing to support post polio-eradication biosafety goals.
Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 53 citations in OpenAlex.
- Article
- Atomic Force Microscopy of Poliovirus Particles After Inactivation by Chemical Methods and Accelerated Electrons.Viruses · 2025Article
- Sabin inactivated polio vaccine upstream process development using fixed-bed bioreactor technology.Vaccine · 2025Article
- Current and next-generation formulation strategies for inactivated polio vaccines to lower costs, increase coverage, and facilitate polio eradication.Human vaccines & immunotherapeutics · 2022Review
- Development of an animal component free production process for Sabin inactivated polio vaccine.Vaccine: X · 2022Article
- VaxArray immunoassay for the multiplexed quantification of poliovirus D-antigen.Journal of immunological methods · 2022Article
- Vero cell upstream bioprocess development for the production of viral vectors and vaccines.Biotechnology advances · 2020Review
- Characterization of Coxsackievirus B4 virus-like particles VLP produced by the recombinant baculovirus-insect cell system expressing the major capsid protein.Molecular biology reports · 2020Article
- Kinetic model for adherent Vero cell growth and poliovirus production in batch bioreactors.Process biochemistry (Barking, London, England) · 2019Article
- Comparison of data science workflows for root cause analysis of bioprocesses.Bioprocess and biosystems engineering · 2019Article
- Analyzed immunogenicity of fractional doses of Sabin-inactivated poliovirus vaccine (sIPV) with intradermal delivery in rats.Human vaccines & immunotherapeutics · 2016Article
- A polyvalent inactivated rhinovirus vaccine is broadly immunogenic in rhesus macaques.Nature communications · 2016Article
- Hematopoietic cancer cell lines can support replication of Sabin poliovirus type 1.BioMed research international · 2015Article
- Combination vaccines against diarrheal diseases.Human vaccines & immunotherapeutics · 2015Review
- Improved poliovirus D-antigen yields by application of different Vero cell cultivation methods.Vaccine · 2014Article
- Current trends in West Nile virus vaccine development.Expert review of vaccines · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Worldwide efforts to eradicate polio caused a tipping point in polio vaccination strategies. A switch from the oral polio vaccine, which can cause circulating and virulent vaccine derived polioviruses, to inactivated polio vaccines (IPV) is scheduled. Moreover, a manufacturing process, using attenuated virus strains instead of wild-type polioviruses, is demanded to enhance worldwide production of IPV, especially in low- and middle income countries. Therefore, development of an IPV from attenuated (Sabin) poliovirus strains (sIPV) was pursued. Starting from the current IPV production process based on wild type Salk strains, adaptations, such as lower virus cultivation temperature, were implemented. sIPV was produced at industrial scale followed by formulation of both plain and aluminium adjuvanted sIPV. The final products met the quality criteria, were immunogenic in rats, showed no toxicity in rabbits and could be released for testing in the clinic. Concluding, sIPV was developed to manufacturing scale. The technology can be transferred worldwide to support post polio-eradication biosafety goals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.